AACR Annual Meeting 2018
Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of DIPG
Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of DIPG
An open-label, biomarker driven, Phase 1/2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed MGMT-unmethylated GBM
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with bevacizumab-naïve recurrent glioblastoma, MGMT-unmethylated
Dianhydrogalactitol (VAL-083) overcomes chemoresistance in pediatric malignant brain tumors and displays synergy with topoisomerase inhibitors
The distinct cytotoxic mechanism of dianhydrogalactitol (VAL-083) overcomes chemoresistance and provides new opportunities for combination therapy in the treatment of glioblastoma
Clinical Trials with dianhydrogalactitol (VAL-083) in MGMT-unmethylated Glioblastoma
DNA damaging agent dianhydrogalactitol (VAL-083) targets HR repair pathway and suggests combination therapy with topoisomerase and PARP inhibitors
Distinct mechanism of action of DNA damaging agent dianhydrogalactitol (VAL-083) suggests combination therapy with PARP inhibitors
Dianhydrogalactitol (VAL-083) overcomes p53-mediated chemo-resistance and displays synergy with topoisomerase inhibitors
Clinical trials of VAL-083 in patients with chemo-resistant glioblastoma